{"created":"2023-05-15T14:48:40.979508+00:00","id":66693,"links":{},"metadata":{"_buckets":{"deposit":"afdb033c-f519-4755-b720-4821733d45b0"},"_deposit":{"created_by":1,"id":"66693","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"66693"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00066693","sets":["10:29"]},"author_link":["655834","655819","655830","655814","655832","655827","655823","655833","655816","655821","655822","655815","655813","655820","655818","655828","655824","655825","655831","655826","655817","655829"],"item_10005_date_7":{"attribute_name":"発表年月日","attribute_value_mlt":[{"subitem_date_issued_datetime":"2016-06-14","subitem_date_issued_type":"Issued"}]},"item_10005_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Beta-emitting meta-131I-iodo-benzylguanidine (MIBG) has been used in the treatment of malignant pheochromocytoma (PHEO). However the effects of MIBG and 5-year survival are limited. Alpha-emitters strongly suppress the growth of tumor cells. 211Astatine (211At) is an α-emitting halogen and has a suitable half-life for cancer therapy (t1/2=7.2 h). Therefore, meta-211At-astatobenzylguanidine (MABG) may potentially suppress the growth of malignant PHEO. In this study, we synthesized MABG and investigate the therapeutic effects of MABG in a rat PHEO model. 211At was produced via the 209Bi(α,2n)211At reaction and was isolated through dry distillation. MABG was synthesized by astatination of meta-trimethylsilylbenzylguanidine hemisulfate. MABG was highly taken up into a rat PHEO cell line, PC-12, through the norepinephrine transporter, and significantly suppressed clonogenic growth. DNA damage and cell cycle arrest at the G2/M phase were observed after MABG treatment. Biodistribution and therapeutic effects were examined using mice bearing PC-12. MABG was highly distributed and was retained in tumors. Furthermore, the tumor size was significantly reduced by the single administration of MABG (555 kBq/head) without an associated weight reduction. These results suggest that MABG might be an attractive therapeutic agent for the treatment of malignant PHEO.","subitem_description_type":"Abstract"}]},"item_10005_description_6":{"attribute_name":"会議概要（会議名, 開催地, 会期, 主催者等）","attribute_value_mlt":[{"subitem_description":"Society of Nuclear Medicine and Molecular Imaging 2016 Annual Meeting","subitem_description_type":"Other"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"大島, 康宏"}],"nameIdentifiers":[{"nameIdentifier":"655813","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"渡辺, 茂樹"}],"nameIdentifiers":[{"nameIdentifier":"655814","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"辻, 厚至"}],"nameIdentifiers":[{"nameIdentifier":"655815","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"永津, 弘太郎"}],"nameIdentifiers":[{"nameIdentifier":"655816","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"坂下, 哲哉"}],"nameIdentifiers":[{"nameIdentifier":"655817","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"杉山, 僚"}],"nameIdentifiers":[{"nameIdentifier":"655818","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"原田, 良信"}],"nameIdentifiers":[{"nameIdentifier":"655819","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"脇, 厚生"}],"nameIdentifiers":[{"nameIdentifier":"655820","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"吉永, 恵一郎"}],"nameIdentifiers":[{"nameIdentifier":"655821","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"東, 達也"}],"nameIdentifiers":[{"nameIdentifier":"655822","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"石岡, 典子"}],"nameIdentifiers":[{"nameIdentifier":"655823","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"大島 康宏","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"655824","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"渡辺 茂樹","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"655825","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"辻 厚至","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"655826","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"永津 弘太郎","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"655827","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"坂下 哲哉","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"655828","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"杉山 僚","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"655829","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"原田 良信","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"655830","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"脇 厚生","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"655831","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"吉永 恵一郎","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"655832","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"東 達也","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"655833","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"石岡 典子","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"655834","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"conference object","resourceuri":"http://purl.org/coar/resource_type/c_c94f"}]},"item_title":"Therapeutic efficacy of α-emitter meta-211At-astato-benzylguanidine (MABG) in a pheochromocytoma model","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Therapeutic efficacy of α-emitter meta-211At-astato-benzylguanidine (MABG) in a pheochromocytoma model"}]},"item_type_id":"10005","owner":"1","path":["29"],"pubdate":{"attribute_name":"公開日","attribute_value":"2018-03-26"},"publish_date":"2018-03-26","publish_status":"0","recid":"66693","relation_version_is_last":true,"title":["Therapeutic efficacy of α-emitter meta-211At-astato-benzylguanidine (MABG) in a pheochromocytoma model"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T20:46:03.489982+00:00"}